See more : Legend Holdings Corporation (3396.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Kinnate Biopharma Inc. (KNTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kinnate Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Intralot S.A. Integrated Lottery Systems and Services (IRLTF) Income Statement Analysis – Financial Results
- The Healing Company Inc. (HLCO) Income Statement Analysis – Financial Results
- AVY Precision Technology INC. (5392.TWO) Income Statement Analysis – Financial Results
- University Bancorp, Inc. (UNIB) Income Statement Analysis – Financial Results
- First Eagle Alternative Capital (FCRZ) Income Statement Analysis – Financial Results
Kinnate Biopharma Inc. (KNTE)
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 799.00K | 604.00K | 123.00K | 83.00K | 0.00 | 0.00 |
| Gross Profit | -799.00K | -604.00K | -123.00K | -83.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 90.77M | 88.15M | 67.17M | 29.24M | 8.96M | 5.68M |
| General & Administrative | 0.00 | 30.37M | 22.95M | 6.76M | 3.06M | 1.96M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.44M | 30.37M | 22.95M | 6.76M | 3.06M | 1.96M |
| Other Expenses | 0.00 | 2.25M | 348.00K | -5.00K | 0.00 | 0.00 |
| Operating Expenses | 118.21M | 118.52M | 90.11M | 36.00M | 12.01M | 7.63M |
| Cost & Expenses | 119.01M | 118.52M | 90.11M | 36.00M | 12.01M | 7.63M |
| Interest Income | 8.53M | 0.00 | 348.00K | 245.00K | 43.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 799.00K | 604.00K | 123.00K | 83.00K | 171.86K | 161.14K |
| EBITDA | -118.21M | -117.92M | -89.99M | -35.92M | -12.01M | -7.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -119.01M | -118.52M | -90.11M | -36.00M | -12.01M | -7.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.36M | 2.25M | 348.00K | 240.00K | 43.00K | 0.00 |
| Income Before Tax | -112.65M | -116.27M | -89.76M | -35.76M | -11.97M | -7.63M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.25M | -348.00K | -328.00K | -43.00K | 0.00 |
| Net Income | -112.65M | -114.02M | -89.42M | -35.43M | -11.93M | -7.63M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| EPS Diluted | -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| Weighted Avg Shares Out | 46.58M | 44.07M | 43.60M | 43.48M | 43.33M | 10.80M |
| Weighted Avg Shares Out (Dil) | 46.58M | 44.07M | 43.60M | 43.48M | 43.33M | 10.80M |
Goldman Sachs Has 5 Stocks Under $10 Rated Buy With 125% to 400% Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its...
Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings
AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index
ATLANTA & NEW YORK--(BUSINESS WIRE)--Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday,...
Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
The KN-8701 trial is a multi-center, open-label, two-part trial of Kinnate's lead RAF inhibitor candidate KIN-2787 The KN-8701 trial is a multi-center, open-label, two-part trial of Kinnate's lead RAF inhibitor candidate KIN-2787
Should You Buy Kinnate Biopharma (KNTE) Ahead of Earnings?
Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021
SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its...
Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021
Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class...
Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Nima...
Source: https://incomestatements.info
Category: Stock Reports